
1. herpes simplex vaccines.

kemble g(8), spaete r(8).
in: arvin a(1), campadelli-fiume g(2), mocarski e(3), moore ps(4), roizman b(5), 
whitley r(6), yamanishi k(7), editors. human herpesviruses: biology, therapy, and
immunoprophylaxis. cambridge: cambridge university press; 2007. chapter 69.

author information: 
(1)stanford university, ca school medicine
(2)university bologna, italy
(3)emory university school medicine, usa
(4)university pittsburgh cancer institute, pa, usa
(5)the university chicago, il, usa
(6)university alabama birmingham, al, usa
(7)osaka university school medicine, japan
(8)medimmune vaccines, inc., mountain view, ca, usa

genital herpes, caused herpes simplex virus (hsv) types 1 2, can
result painful vesicular ulcerative lesions genitalia the
genital tract, may cause urologic neurologic problems. following
primary infection, hsv establishes latent infection local ganglia and
can reactivate multiple occasions manifestations ranging from
asymptomatic viral shedding painful recurrences genital orofacial
lesions (whitley, 2001). hsv-2 predominant etiologic agent genital
herpes data second third national health nutrition
examination surveys, spanning 1976 1994, demonstrated prevalence of
hsv-2 infection increased 30% since late 1970â€™s highest rates 
teenagers young adults (fleming et al., 1997). estimated than
1.6 million individuals infected annually hsv-2 usa (armstrong et
al., 2001). perspective vaccine development, however, genital herpes 
caused hsv-1 cannot overlooked. although genital herpes caused hsv-1 
generally less severe hsv-2, hsv-1 ubiquitous, infects larger portion
of population hsv-2, percentage hsv-1 positive cultures
isolated individuals presenting genital herpes appears increasing
(ribes et al., 2001).

pmid: 21348132 

